Sugi Predict

Sugi Predict / Compounds / SCHEMBL184425

SCHEMBL184425

SCHEMBL184425

CC(C)(C)OC(=O)NCc1cccc(C(=O)O)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1H4 Q96RI1 1/20 0.61
▸ MEP1B Q16820 5/20 0.50
▸ GLS O94925 3/20 0.50
▸ HDAC1 Q13547 1/20 0.48
▸ FABP4 P15090 1/20 0.48
▸ FOLH1 Q04609 1/20 0.47
▸ MMP13 P45452 1/20 0.47
▸ KDM4A O75164 1/20 0.47
▸ SLC7A5 Q01650 1/20 0.47
▸ CA12 O43570 1/20 0.47
▸ CA1 P00915 1/20 0.47
▸ CA7 P43166 1/20 0.47
▸ CA14 Q9ULX7 1/20 0.47
▸ NPC1 O15118 1/20 0.47
▸ MITF O75030 1/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ BRD4 O60885 1/20 0.47
▸ NAMPT P43490 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16397304 0.92 FNTA (0.55) NR1H4GLSHDAC1BRD4
SCHEMBL21481481 0.90 AKR1C3 (0.51) NR1H4GLSMMP13NPC1RAB9A
SCHEMBL13135999 0.89 GLS (0.50) NR1H4GLSHDAC1MMP13KDM4A
SCHEMBL21455594 0.88 NR1H4 (0.48) NR1H4GLSHDAC1MMP13KDM4A
SCHEMBL879574 0.87 LOXL2 (0.56) NR1H4GLSFOLH1MMP13KDM4A
SCHEMBL31044413 0.87 GLS (0.49) NR1H4GLSHDAC1MMP13KDM4A
SCHEMBL320558 0.86 NQO2 (0.50) NR1H4FOLH1SLC7A5CA1NPC1
SCHEMBL24140014 0.86 ALDH1A1 (0.49) NR1H4GLSHDAC1MMP13KDM4A
SCHEMBL20474743 0.86 HDAC6 (0.56) NR1H4GLSHDAC1MMP13NAMPT
SCHEMBL2570189 0.85 HDAC1 (0.63) NR1H4HDAC1NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 505 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260000781-A1 FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF CIDARA THERAPEUTICS INC (US) 2026-01-01 — — US disclosed
EP-3966226-B1 MASP INHIBITORY COMPOUNDS AND USES THEREOF BAYER AG (DE) 2025-12-24 — — EP disclosed
US-12503491-B2 MASP inhibitory compounds and uses thereof BAYER AKTIENGESELLSCHAFT (DE) 2025-12-23 — — US disclosed
WO-2025231152-A1 COMPOUNDS AND METHODS FOR RESTORING BETA-ADRENERGIC RECEPTOR FUNCTION THE CLEVELAND CLINIC FOUNDATION (US) 2025-11-06 — — WO disclosed
US-12383560-B2 Compounds and uses thereof FOGHORN THERAPEUTICS INC. (US) 2025-08-12 — — US disclosed
US-20250163030-A1 PYRIDIZIN-3(2H)-ONE DERIVATIVES GILEAD SCIENCES, INC. 2025-05-22 — — US disclosed
EP-4551563-A2 FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF CIDARA THERAPEUTICS, INC. (US) 2025-05-14 — — EP disclosed
WO-2025085848-A1 ANTIBACTERIAL COMPOUNDS ARREPATH, INC. (US) 2025-04-24 — — WO disclosed
CN-119816487-A FC conjugates comprising CD73 inhibitors and uses thereof 奇达拉治疗公司 2025-04-11 — — CN disclosed
US-20250116030-A1 Two-Dimensional Halide Perovskite Nanowires PURDUE RESEARCH FOUNDATION (US) 2025-04-10 — — US disclosed
WO-1995000472-A1 1,2 DIACYLATED HYDRAZINE DERIVATIVES AND THEIR USE AS ALL ADHESION INHIBITORS ZENECA LIMITED (GB) 1995-01-05 — — WO disclosed
EP-0632016-A1 1,2-Diacylated hydrazine derivatives and their use as cell adhesion inhibitors ZENECA LIMITED (GB) 1995-01-04 — — EP disclosed
EP-0625164-A1 CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1994-11-23 — — EP disclosed
WO-1994022910-A1 CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1994-10-13 — — WO disclosed
WO-1994022494-A1 RADIOLABELED PLATELET GPIIb/IIIa RECEPTOR ANTAGONISTS AS IMAGING AGENTS FOR THE DIAGNOSIS OF THROMBOEMBOLIC DISORDERS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1994-10-13 — — WO disclosed
US-5231102-A Tetrahydroquinoline derivatives useful for neurodegenerative disorders MERCK SHARP & DOHME, LTD. (GB) 1993-07-27 — — US disclosed
WO-1993007170-A1 CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1993-04-15 — — WO disclosed
US-5039805-A Novel benzoic and phenylacetic acid derivatives HOFFMANN-LA ROCHE INC. (US) 1991-08-13 — — US disclosed
EP-0386839-A2 Tetrahydroquinoline derivatives useful for neurodegenerative disorders MERCK SHARP & DOHME LTD. (GB) 1990-09-12 — — EP disclosed
EP-0271041-A2 Atrial peptide derivatives ABBOTT LABORATORIES (US) 1988-06-15 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12503491-B2 MASP inhibitory compounds and uses thereof MASP2, SERPINB1, SPINT2 NR1H4 4031/4885MEP1B 230/4885GLS 197/4885
US-12383560-B2 Compounds and uses thereof VHL, CLN6, TFEB NR1H4 1624/4885MEP1B 1421/4885GLS 292/4885
US-20250163030-A1 PYRIDIZIN-3(2H)-ONE DERIVATIVES PIR, CYP3A43, CYP1A2 NR1H4 1889/4885MEP1B 879/4885GLS 1497/4885
US-20260000781-A1 FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF FCGR2A, FCGR1A, FCGR3B NR1H4 1856/4885MEP1B 500/4885GLS 1094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.